Fenretinide in Treating Patients With Cervical Neoplasia
RATIONALE: Chemoprevention uses drugs to try and prevent development of cancer. Fenretinide may be effective in treating cervical neoplasia and preventing cervical cancer.
PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of fenretinide to placebo in treating patients with cervical neoplasia.
|Cervical Cancer Precancerous Condition||Drug: Fenretinide Other: Placebo||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
|Official Title:||A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3|
- Efficacy of Fenretinide at Regressing CIN [ Time Frame: 6 months ]
|Study Start Date:||September 1992|
|Study Completion Date:||May 2001|
|Primary Completion Date:||September 2000 (Final data collection date for primary outcome measure)|
Oral Fenretinide daily for 6 months with 3 days of rest every month.
Other Name: 4-HPR
|Placebo Comparator: Placebo||
Oral placebo daily for 6 months with 3 days of rest every month.
OBJECTIVES: I. Determine the efficacy of fenretinide (N-(4-hydroxyphenyl) retinamide; 4-HPR) at regressing cervical intraepithelial neoplasia (CIN). II. Document the qualitative and quantitative toxicity of 4-HPR in women with CIN.
OUTLINE: This is a double blinded study. Patients are randomized to receive either fenretinide or placebo. Patients are administered fenretinide or a placebo by mouth (PO) daily for 6 months with 3 days of rest every month. Patients undergo colposcopy, colpophotography, and Pap smears at 3, 6, 9, and 12 months. Patients undergo cervical biopsy at 6 and 12 months to assess changes.
PROJECTED ACCRUAL: 84-100 patients will be accrued.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003075
|United States, Texas|
|University of Texas - MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Study Chair:||Michele Follen, MD, PhD||M.D. Anderson Cancer Center|